Sichuan Biokin PharmaceuticalLtd Future Growth
Future criteria checks 0/6
Sichuan Biokin PharmaceuticalLtd's revenue and earnings are forecast to decline at 36.8% and 102% per annum respectively. EPS is expected to decline by 102% per annum. Return on equity is forecast to be -4% in 3 years.
Key information
-102.0%
Earnings growth rate
-102.0%
EPS growth rate
| Pharmaceuticals earnings growth | 18.9% |
| Revenue growth rate | -36.8% |
| Future return on equity | -4.0% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,966 | -86 | -1,190 | -208 | 2 |
| 12/31/2025 | 2,413 | 70 | 676 | 842 | 2 |
| 12/31/2024 | 6,174 | 3,770 | 3,042 | 3,024 | 2 |
| 9/30/2024 | 5,847 | 3,800 | 4,290 | 4,359 | N/A |
| 6/30/2024 | 5,804 | 4,214 | 4,673 | 4,736 | N/A |
| 3/31/2024 | 5,901 | 4,391 | 4,890 | 4,952 | N/A |
| 12/31/2023 | 562 | -780 | -697 | -615 | N/A |
| 9/30/2023 | 601 | -555 | -570 | -513 | N/A |
| 6/30/2023 | 710 | -473 | -483 | -434 | N/A |
| 3/31/2023 | 705 | -404 | -395 | -351 | N/A |
| 12/31/2022 | 703 | -282 | -293 | -259 | N/A |
| 9/30/2022 | 663 | -320 | -345 | -304 | N/A |
| 12/31/2021 | 797 | -100 | -180 | -135 | N/A |
| 12/31/2020 | 1,013 | 38 | 63 | 78 | N/A |
| 12/31/2019 | 1,207 | 8 | 7 | 28 | N/A |
| 12/31/2014 | 418 | 17 | N/A | 13 | N/A |
| 12/31/2013 | 415 | 35 | N/A | 26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688506's earnings are forecast to decline over the next 3 years (-102% per year).
Earnings vs Market: 688506's earnings are forecast to decline over the next 3 years (-102% per year).
High Growth Earnings: 688506's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 688506's revenue is expected to decline over the next 3 years (-36.8% per year).
High Growth Revenue: 688506's revenue is forecast to decline over the next 3 years (-36.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688506 is forecast to be unprofitable in 3 years.